These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
447 related articles for article (PubMed ID: 27044098)
1. Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival. Kloepper J; Riedemann L; Amoozgar Z; Seano G; Susek K; Yu V; Dalvie N; Amelung RL; Datta M; Song JW; Askoxylakis V; Taylor JW; Lu-Emerson C; Batista A; Kirkpatrick ND; Jung K; Snuderl M; Muzikansky A; Stubenrauch KG; Krieter O; Wakimoto H; Xu L; Munn LL; Duda DG; Fukumura D; Batchelor TT; Jain RK Proc Natl Acad Sci U S A; 2016 Apr; 113(16):4476-81. PubMed ID: 27044098 [TBL] [Abstract][Full Text] [Related]
2. Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages. Peterson TE; Kirkpatrick ND; Huang Y; Farrar CT; Marijt KA; Kloepper J; Datta M; Amoozgar Z; Seano G; Jung K; Kamoun WS; Vardam T; Snuderl M; Goveia J; Chatterjee S; Batista A; Muzikansky A; Leow CC; Xu L; Batchelor TT; Duda DG; Fukumura D; Jain RK Proc Natl Acad Sci U S A; 2016 Apr; 113(16):4470-5. PubMed ID: 27044097 [TBL] [Abstract][Full Text] [Related]
3. Anti-tumoral, anti-angiogenic and anti-metastatic efficacy of a tetravalent bispecific antibody (TAvi6) targeting VEGF-A and angiopoietin-2. Scheuer W; Thomas M; Hanke P; Sam J; Osl F; Weininger D; Baehner M; Seeber S; Kettenberger H; Schanzer J; Brinkmann U; Weidner KM; Regula J; Klein C MAbs; 2016; 8(3):562-73. PubMed ID: 26864324 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of a Bispecific Antibody Co-Targeting VEGFA and Ang-2 in Combination with Chemotherapy in a Chemoresistant Colorectal Carcinoma Xenograft Model. Mueller T; Freystein J; Lucas H; Schmoll HJ Molecules; 2019 Aug; 24(16):. PubMed ID: 31394786 [TBL] [Abstract][Full Text] [Related]
5. Effect of Ang-2-VEGF-A Bispecific Antibody in Renal Cell Carcinoma. Bessho H; Wong B; Huang D; Tan J; Ong CK; Iwamura M; Hart S; Dangl M; Thomas M; Teh BT Cancer Invest; 2015; 33(8):378-86. PubMed ID: 26115098 [TBL] [Abstract][Full Text] [Related]
6. Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficacy. Kienast Y; Klein C; Scheuer W; Raemsch R; Lorenzon E; Bernicke D; Herting F; Yu S; The HH; Martarello L; Gassner C; Stubenrauch KG; Munro K; Augustin HG; Thomas M Clin Cancer Res; 2013 Dec; 19(24):6730-40. PubMed ID: 24097868 [TBL] [Abstract][Full Text] [Related]
7. SDF-1 Blockade Enhances Anti-VEGF Therapy of Glioblastoma and Can Be Monitored by MRI. Deng L; Stafford JH; Liu SC; Chernikova SB; Merchant M; Recht L; Martin Brown J Neoplasia; 2017 Jan; 19(1):1-7. PubMed ID: 27940247 [TBL] [Abstract][Full Text] [Related]
8. Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastoma. Scholz A; Harter PN; Cremer S; Yalcin BH; Gurnik S; Yamaji M; Di Tacchio M; Sommer K; Baumgarten P; Bähr O; Steinbach JP; Trojan J; Glas M; Herrlinger U; Krex D; Meinhardt M; Weyerbrock A; Timmer M; Goldbrunner R; Deckert M; Braun C; Schittenhelm J; Frueh JT; Ullrich E; Mittelbronn M; Plate KH; Reiss Y EMBO Mol Med; 2016 Jan; 8(1):39-57. PubMed ID: 26666269 [TBL] [Abstract][Full Text] [Related]
9. Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy. Lucio-Eterovic AK; Piao Y; de Groot JF Clin Cancer Res; 2009 Jul; 15(14):4589-99. PubMed ID: 19567589 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of Combination Therapy with MET and VEGF Inhibitors for MET-overexpressing Glioblastoma. Okuda T; Tasaki T; Nakata S; Yamashita K; Yoshioka H; Izumoto S; Kato A; Fujita M Anticancer Res; 2017 Jul; 37(7):3871-3876. PubMed ID: 28668888 [TBL] [Abstract][Full Text] [Related]
11. Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF. Di Tacchio M; Macas J; Weissenberger J; Sommer K; Bähr O; Steinbach JP; Senft C; Seifert V; Glas M; Herrlinger U; Krex D; Meinhardt M; Weyerbrock A; Timmer M; Goldbrunner R; Deckert M; Scheel AH; Büttner R; Grauer OM; Schittenhelm J; Tabatabai G; Harter PN; Günther S; Devraj K; Plate KH; Reiss Y Cancer Immunol Res; 2019 Dec; 7(12):1910-1927. PubMed ID: 31597643 [TBL] [Abstract][Full Text] [Related]
12. CD44 expression in the tumor periphery predicts the responsiveness to bevacizumab in the treatment of recurrent glioblastoma. Nishikawa M; Inoue A; Ohnishi T; Yano H; Kanemura Y; Kohno S; Ohue S; Ozaki S; Matsumoto S; Suehiro S; Nakamura Y; Shigekawa S; Watanabe H; Kitazawa R; Tanaka J; Kunieda T Cancer Med; 2021 Mar; 10(6):2013-2025. PubMed ID: 33543833 [TBL] [Abstract][Full Text] [Related]
13. Shevtsov M; Pitkin E; Ischenko A; Stangl S; Khachatryan W; Galibin O; Edmond S; Lobinger D; Multhoff G Front Immunol; 2019; 10():454. PubMed ID: 30967859 [TBL] [Abstract][Full Text] [Related]
14. 18F-FET microPET and microMRI for anti-VEGF and anti-PlGF response assessment in an orthotopic murine model of human glioblastoma. Nedergaard MK; Michaelsen SR; Urup T; Broholm H; El Ali H; Poulsen HS; Stockhausen MT; Kjaer A; Lassen U PLoS One; 2015; 10(2):e0115315. PubMed ID: 25680186 [TBL] [Abstract][Full Text] [Related]
15. Angiopoietin-2 interferes with anti-VEGFR2-induced vessel normalization and survival benefit in mice bearing gliomas. Chae SS; Kamoun WS; Farrar CT; Kirkpatrick ND; Niemeyer E; de Graaf AM; Sorensen AG; Munn LL; Jain RK; Fukumura D Clin Cancer Res; 2010 Jul; 16(14):3618-27. PubMed ID: 20501615 [TBL] [Abstract][Full Text] [Related]
16. VEGF as a modulator of the innate immune response in glioblastoma. Turkowski K; Brandenburg S; Mueller A; Kremenetskaia I; Bungert AD; Blank A; Felsenstein M; Vajkoczy P Glia; 2018 Jan; 66(1):161-174. PubMed ID: 28948650 [TBL] [Abstract][Full Text] [Related]
17. Antiangiogenic effects of ganetespib in colorectal cancer mediated through inhibition of HIF-1α and STAT-3. Nagaraju GP; Park W; Wen J; Mahaseth H; Landry J; Farris AB; Willingham F; Sullivan PS; Proia DA; El-Hariry I; Taliaferro-Smith L; Diaz R; El-Rayes BF Angiogenesis; 2013 Oct; 16(4):903-17. PubMed ID: 23838996 [TBL] [Abstract][Full Text] [Related]
18. Effects of VEGF blockade on the dynamics of the inflammatory landscape in glioblastoma-bearing mice. Soubéran A; Brustlein S; Gouarné C; Chasson L; Tchoghandjian A; Malissen M; Rougon G J Neuroinflammation; 2019 Oct; 16(1):191. PubMed ID: 31660979 [TBL] [Abstract][Full Text] [Related]
19. Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy. Castro BA; Flanigan P; Jahangiri A; Hoffman D; Chen W; Kuang R; De Lay M; Yagnik G; Wagner JR; Mascharak S; Sidorov M; Shrivastav S; Kohanbash G; Okada H; Aghi MK Oncogene; 2017 Jun; 36(26):3749-3759. PubMed ID: 28218903 [TBL] [Abstract][Full Text] [Related]
20. An immunodepletion procedure advances free angiopoietin-2 determination in human plasma samples during anti-cancer therapy with bispecific anti-Ang2/VEGF CrossMab. Stubenrauch K; Wessels U; Essig U; Vogel R; Waltenberger H; Hansbauer A; Koehler A; Heinrich J J Pharm Biomed Anal; 2015 Jan; 102():459-67. PubMed ID: 25459946 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]